Investing in Late-Stage Clinical Trials and Manufacturing of Neglected Disease Product Candidates – Modeling the Benefits and Costs of Investments for Three Middle-Income Countries
Publication
, Journal Article
Schäferhoff, M; Zimmerman, A; Mustafa Diab, M; Mao, W; Chowdhary, V; Gill, D; Karanja, R; Madikizela, M; Ogbuoji, O; Yamey, G
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Schäferhoff, M., Zimmerman, A., Mustafa Diab, M., Mao, W., Chowdhary, V., Gill, D., … Yamey, G. (n.d.). Investing in Late-Stage Clinical Trials and Manufacturing of Neglected Disease Product Candidates – Modeling the Benefits and Costs of Investments for Three Middle-Income Countries.
Schäferhoff, Marco, Armand Zimmerman, Mohamed Mustafa Diab, Wenhui Mao, Vipul Chowdhary, Davinder Gill, Robert Karanja, Mziwandile Madikizela, Osondu Ogbuoji, and Gavin Yamey. “Investing in Late-Stage Clinical Trials and Manufacturing of Neglected Disease Product Candidates – Modeling the Benefits and Costs of Investments for Three Middle-Income Countries,” n.d.
Schäferhoff M, Zimmerman A, Mustafa Diab M, Mao W, Chowdhary V, Gill D, et al. Investing in Late-Stage Clinical Trials and Manufacturing of Neglected Disease Product Candidates – Modeling the Benefits and Costs of Investments for Three Middle-Income Countries.
Schäferhoff M, Zimmerman A, Mustafa Diab M, Mao W, Chowdhary V, Gill D, Karanja R, Madikizela M, Ogbuoji O, Yamey G. Investing in Late-Stage Clinical Trials and Manufacturing of Neglected Disease Product Candidates – Modeling the Benefits and Costs of Investments for Three Middle-Income Countries.